Exelixis Dirección

Dirección controles de criterios 2/4

Exelixis' El consejero delegado es Mike Morrissey , nombrado en Jul 2010, tiene un mandato de 13.42 años. la remuneración anual total es $16.88M , compuesta por 6.8% salario y 93.2% primas, incluidas acciones y opciones de la empresa. posee directamente 0.47% de las acciones de la empresa, por valor de $32.07M . La antigüedad media del equipo directivo y del consejo de administración es de 8.3 años y 10.3 años respectivamente.

Información clave

Mike Morrissey

Chief Executive Officer (CEO)

US$16.9m

Compensación total

Porcentaje del salario del CEO	6.8%
Permanencia del CEO	13.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	8.7yrs
Promedio de permanencia en la Junta Directiva	10.7yrs

Actualizaciones recientes de la dirección

Recent updates

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs

Jul 07

Exelixis: Becoming A Giant Pharma

May 18

Exelixis: Beyond The Cabozantinib Franchise

Apr 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mike Morrissey en comparación con los beneficios de Exelixis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$208m
Sep 30 2023	n/a	n/a	US$92m
Jun 30 2023	n/a	n/a	US$164m
Mar 31 2023	n/a	n/a	US$154m
Dec 31 2022	US$17m	US$1m	US$182m
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m

Compensación vs. Mercado: Mike($USD16.88M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.88M).

Compensación vs. Ingresos: Mikeha aumentado más de un 20% en el último año.

CEO

Mike Morrissey (62 yo)

13.8yrs

Permanencia

US$16,877,545

Compensación

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.3yrs	US$465.07k	0.41% $ 29.4m
Michael Morrissey	CEO, President & Director	13.8yrs	US$16.88m	0.50% $ 35.9m
Christopher Senner	Executive VP & CFO	8.8yrs	US$5.18m	0.14% $ 10.1m
Jeffrey Hessekiel	Executive VP	10.2yrs	US$4.62m	0.12% $ 8.7m
Patrick Haley	Executive Vice President of Commercial	7.3yrs	US$4.65m	0.039% $ 2.8m
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	1.3yrs	sin datos	0.071% $ 5.1m
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	7.3yrs	sin datos	sin datos
Laura Dillard	Executive Vice President of Human Resources	9.4yrs	sin datos	sin datos
Peter Lamb	Executive VP of Scientific Strategy	1.3yrs	US$1.96m	0.10% $ 7.3m
Anne Champsaur	Senior Vice President of Drug Safety	9yrs	sin datos	sin datos
William Berg	Senior Vice President of Medical Affairs	8.6yrs	sin datos	sin datos
Stefan Krauss	VP & Head of Business Development	no data	sin datos	sin datos

8.7yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: EXELEl equipo directivo de la empresa es veterano y experimentado (8.3 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.3yrs	US$465.07k	0.41% $ 29.4m
Michael Morrissey	CEO, President & Director	13.8yrs	US$16.88m	0.50% $ 35.9m
Jack Wyszomierski	Independent Director	20.2yrs	US$441.07k	0.10% $ 7.5m
George Poste	Independent Director	19.7yrs	US$431.07k	0.064% $ 4.6m
Alan Garber	Independent Director	19.3yrs	US$438.44k	0.012% $ 845.8k
Charles Sawyers	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Ronald Evans	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Julie Smith	Independent Director	7.6yrs	US$453.44k	sin datos
Maria Freire	Independent Director	6yrs	US$429.57k	0.020% $ 1.4m
Jacqueline Wright	Independent Director	2.3yrs	US$424.60k	0.0051% $ 364.7k
Robert Oliver	Independent Director	less than a year	sin datos	sin datos
Tomas Heyman	Independent Director	less than a year	sin datos	sin datos

10.7yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: EXELLos consejos de administración de la empresa son veteranos y experimentados ( 10.3 años de permanencia media en el cargo).

Exelixis Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

Executive Vice President of Commercial notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

CEO, President & Director exercised options and sold US$2.1m worth of stock

Recent updates

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Consensus EPS estimates fall by 15%

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

CEO, President & Director exercised options and sold US$816k worth of stock

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Insider exercised options and sold US$234k worth of stock

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Independent Director notifies of intention to sell stock

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Provides Revenue Guidance for 2022

Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Executive Vice President of Commercial notifies of intention to sell stock

Exelixis: Efforts Continue To Diversify The Pipeline

Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Exelixis, Teva fight over Cabometyx generic again

Executive VP & CFO exercised options and sold US$2.0m worth of stock